DE602006011859D1 - T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon - Google Patents

T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Info

Publication number
DE602006011859D1
DE602006011859D1 DE602006011859T DE602006011859T DE602006011859D1 DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1 DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 T DE602006011859 T DE 602006011859T DE 602006011859 D1 DE602006011859 D1 DE 602006011859D1
Authority
DE
Germany
Prior art keywords
individuals
laten
barr
epstein
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006011859T
Other languages
German (de)
English (en)
Inventor
Veronique Pancre
Claude Auriault
Stephane Depil
Bernard Maillere
Olivier Morales
Gaetan Munier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Université Lille 2 Droit et Santé
Original Assignee
Centre National de la Recherche Scientifique
Commissariat a lEnergie Atomique CEA
Université Lille 2 Droit et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Commissariat a lEnergie Atomique CEA, Université Lille 2 Droit et Santé filed Critical Centre National de la Recherche Scientifique
Publication of DE602006011859D1 publication Critical patent/DE602006011859D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006011859T 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon Expired - Lifetime DE602006011859D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501198A FR2881746B1 (fr) 2005-02-07 2005-02-07 Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
PCT/FR2006/000229 WO2006082313A2 (fr) 2005-02-07 2006-02-02 Epitopes t cd4+ des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus db la population caucasienne et leurs applications

Publications (1)

Publication Number Publication Date
DE602006011859D1 true DE602006011859D1 (de) 2010-03-11

Family

ID=35116028

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006011859T Expired - Lifetime DE602006011859D1 (de) 2005-02-07 2006-02-02 T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon

Country Status (8)

Country Link
US (1) US20090130134A1 (cg-RX-API-DMAC7.html)
EP (1) EP1861418B1 (cg-RX-API-DMAC7.html)
JP (1) JP4972562B2 (cg-RX-API-DMAC7.html)
AT (1) ATE455791T1 (cg-RX-API-DMAC7.html)
CA (1) CA2596929C (cg-RX-API-DMAC7.html)
DE (1) DE602006011859D1 (cg-RX-API-DMAC7.html)
FR (1) FR2881746B1 (cg-RX-API-DMAC7.html)
WO (1) WO2006082313A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011699A1 (en) * 1993-10-29 1995-05-04 The Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
FR2830940B1 (fr) 2001-10-17 2007-06-15 Commissariat Energie Atomique Procede de selection de ligands d'hla-dp4 et ses applications
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
BRPI0815395A2 (pt) 2007-08-15 2015-02-10 Circassia Ltd Composição, vetor, produto, formulação farmacêutica, me´todo in vitro para determinar se as células t reconhecem um polipeptídeo, e, método in vitro para determinar se um indivíduo se encontra ou está em risco de uma condição.
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
WO2011072086A1 (en) 2009-12-08 2011-06-16 Hemaquest Pharmaceuticals, Inc. Methods and low dose regimens for treating red blood cell disorders
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
CA3132353A1 (en) 2012-05-08 2013-11-14 The Johns Hopkins University Methods and compositions for infusion of transiently engrafting, selected populations of allogeneic lymphocytes to treat cancer
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
CA2971677A1 (en) 2014-12-23 2016-06-30 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
KR20200101394A (ko) 2017-12-20 2020-08-27 글락소스미스클라인 바이오로지칼즈 에스.에이. 엡스타인-바 바이러스 항원 구축물
CA3124457A1 (en) * 2018-12-21 2020-06-25 Biontech Us Inc. Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
TWI853940B (zh) 2019-05-31 2024-09-01 美商維拉克塔股份有限公司 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
IL295241B1 (en) * 2020-02-10 2026-06-01 Univ Johns Hopkins Cancer immunotherapy using allogeneic and tumor-specific T-cell and CD4 cell transfusions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040157780A1 (en) * 1993-11-29 2004-08-12 Epimmune Inc. CTL inducing peptides from c-erb2 (HER-2/neu)
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
US20020141995A1 (en) * 1997-06-10 2002-10-03 Irvin Charles G. Method for treatment of inflammatory disease
CA2392456A1 (en) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Assays and therapies for latent viral infection
EP1229043A1 (en) * 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0214528D0 (en) * 2002-06-24 2002-08-07 Univ Aberdeen Materials and methods for induction of immune tolerance
AU2003246485A1 (en) * 2002-07-16 2004-02-02 Affinium Pharmaceuticals, Inc. Interactions of the epstein-barr virus protein ebna1, and uses thereof
WO2004041849A1 (en) * 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
US20040141995A1 (en) * 2002-12-10 2004-07-22 Rongfu Wang MHC class I-restricted and MHC class II-restricted EBNA1 peptides

Also Published As

Publication number Publication date
US20090130134A1 (en) 2009-05-21
FR2881746B1 (fr) 2007-04-13
JP2008529486A (ja) 2008-08-07
JP4972562B2 (ja) 2012-07-11
WO2006082313A2 (fr) 2006-08-10
WO2006082313A3 (fr) 2007-01-11
FR2881746A1 (fr) 2006-08-11
EP1861418A2 (fr) 2007-12-05
ATE455791T1 (de) 2010-02-15
CA2596929A1 (fr) 2006-08-10
EP1861418B1 (fr) 2010-01-20
CA2596929C (fr) 2015-12-29

Similar Documents

Publication Publication Date Title
ATE455791T1 (de) T-cd4+-epitope der latenzantigene typ i und ii des epstein-barr-virus, die bei der mehrzahl von individuen in der kaukasischen bevölkerung erkannt werden können, und anwendungen davon
EA201070271A1 (ru) Пептиды для получения вакцины
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
DK2101569T3 (da) Krystallinsk fast rasagilinbase
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
NO20074238L (no) Fiksert dosering av HER-antistoffer
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MX2023000390A (es) Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
CA2821268C (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
TW200728466A (en) Antibody molecules having specificity for human IL-6
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
MA44665B1 (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
EP4448497A4 (en) TETRAHYDROPYRIDAZINES, COMPOSITIONS COMPRISING THEM AND THEIR USES
TW200725839A (en) Stacked wafer or die packaging with enhanced thermal and device performance
WO2009040674A3 (en) A public and immunogenic cd4+ t cell epitope of the hiv tat protein and its applications
WO2010080188A3 (en) Epitope targeted anthrax vaccine
ATE474582T1 (de) Pharmazeutische zusammensetzung enthaltend glucan aus mikroalgen
DK1713438T3 (da) Medicinsk sæbe
WO2006120473A3 (en) Mhc class i and ii peptide antigens derived from tumour antigen 5t4

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: UNIVERSITE DE LILLE II, LILLE, FR

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, , FR